Business
Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones
RAHWAY, N.J., April 30, 2026--Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/c3513d56225df6d19199d2248beff17e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HSbq0LpkWOtTlYjW5VlxPw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQzNA--/https://media.zenfs.com/en/business-wire.com/c3513d56225df6d19199d2248beff17e","width":480,"height":217}},"lazy":false},{"type":"text","content":"Sales Growth Driven by Continued Strength in Oncology and Animal Health, Plus Increasing Contributions From Launches","length":116,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Total Worldwide Sales Were $16.3 Billion (5% Growth; 3% Growth ex-FX)","length":69,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"KEYTRUDA/KEYTRUDA QLEX1 Sales Were $8.0 Billion (12% Growth; 8% Growth ex-FX); Includes KEYTRUDA QLEX Sales of $128 Million","length":123,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"WINREVAIR Sales Were $525 Million (88% Growth; 87% Growth ex-FX)","length":64,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Animal Health Sales Were $1.8 Billion (13% Growth; 6% Growth ex-FX)","length":67,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":254,"olType":false}]},{"val":[{"type":"text","content":"GAAP Loss per Share Was $1.72; Non-GAAP Loss per Share Was $1.28; GAAP and Non-GAAP Loss per Share Include a Charge of $3.62 per Share for the Acquisition of Cidara","length":164,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Presented New Data From Cardio-Pulmonary Pipeline at ACC.26, Including Positive Results From Phase 3 CORALreef AddOn Trial","length":122,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Received U.S. FDA Approval for IDVYNSO, a Once-Daily, Oral Treatment for Certain Adults With Virologically Suppressed HIV-1","length":123,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Achieved Multiple Significant Regulatory and Clinical Milestones Across Oncology Pipeline","length":89,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announced Agreement To Acquire Terns Pharmaceuticals, Inc. and Expand Hematology Pipeline With TERN-701, a Novel Cand...